<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/379j–21" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/379j–21/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/379j–21/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_379j_21"><akn:num>379j–21</akn:num><akn:heading>Authority to assess and use generic new animal drug fees</akn:heading><akn:content><akn:p>§ 379j–21. Authority to assess and use generic new animal drug fees(a) Types of feesBeginning with respect to fiscal year 2009, the Secretary shall assess and collect fees in accordance with this section as follows:(1) Abbreviated application fee(A) In generalEach person that submits, on or after July 1, 2008, an abbreviated application for a generic new animal drug shall be subject to a fee as established in subsection (c) for such an application.


(B) PaymentThe fee required by subparagraph (A) shall be due upon submission of the abbreviated application.


(C) Exceptions(i) Previously filed applicationIf an abbreviated application was submitted by a person that paid the fee for such application, was accepted for filing, and was not approved or was withdrawn (without a waiver or refund), the submission of an abbreviated application for the same product by the same person (or the person’s licensee, assignee, or successor) shall not be subject to a fee under subparagraph (A).


(ii) Certain abbreviated applications involving combination animal drugsAn abbreviated application which is subject to the criteria in section 360b(d)(4) of this title and submitted on or after October 1, 2013 shall be subject to a fee equal to 50 percent of the amount of the abbreviated application fee established in subsection (c).



(D) Refund of fee if application refused for filingThe Secretary shall refund 75 percent of the fee paid under subparagraph (B) for any abbreviated application which is refused for filing.


(E) Refund of fee if application withdrawnIf an abbreviated application is withdrawn after the application was filed, the Secretary may refund the fee or portion of the fee paid under subparagraph (B) if no substantial work was performed on the application after the application was filed. The Secretary shall have the sole discretion to refund the fee under this subparagraph. A determination by the Secretary concerning a refund under this subparagraph shall not be reviewabl</akn:p></akn:content><akn:subsection eId="subsec_379j_21_a"><akn:num>(a)</akn:num><akn:heading>Types of fees</akn:heading><akn:content><akn:p>(a) Types of fees Beginning with respect to fiscal year 2009, the Secretary shall assess and collect fees in accordance with this section as follows:</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_21_b"><akn:num>(b)</akn:num><akn:heading>Fee revenue amounts</akn:heading><akn:content><akn:p>(b) Fee revenue amounts</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_21_c"><akn:num>(c)</akn:num><akn:heading>Annual fee setting; adjustments</akn:heading><akn:content><akn:p>(c) Annual fee setting; adjustments</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_21_d"><akn:num>(d)</akn:num><akn:heading>Fee waiver or reduction</akn:heading><akn:content><akn:p>(d) Fee waiver or reduction The Secretary shall grant a waiver from, or a reduction of, one or more fees assessed under subsection (a) where the Secretary finds that the generic new animal drug is intended solely to provide for a minor use or minor species indication.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_21_e"><akn:num>(e)</akn:num><akn:heading>Effect of failure to pay fees</akn:heading><akn:content><akn:p>(e) Effect of failure to pay fees An abbreviated application for a generic new animal drug submitted by a person subject to fees under subsection (a) shall be considered incomplete and shall not be accepted for filing by the Secretary until all fees owed by such person have been paid. An investigational submission for a generic new animal drug that is submitted by a person subject to fees under subsection (a) shall be considered incomplete and shall not be accepted for review by the Secretary until all fees owed by such person have been paid. A request to establish a generic investigational new animal drug file that is submitted by a person subject to fees under subsection (a) shall be considered incomplete and shall not be accepted for action by the Secretary until all fees owed by such person have been paid. The Secretary may discontinue review of any abbreviated application for a generic new animal drug, supplemental abbreviated application for a generic new animal drug, or investig</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_21_f"><akn:num>(f)</akn:num><akn:heading>Assessment of fees</akn:heading><akn:content><akn:p>(f) Assessment of fees</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_21_g"><akn:num>(g)</akn:num><akn:heading>Crediting and availability of fees</akn:heading><akn:content><akn:p>(g) Crediting and availability of fees</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_21_h"><akn:num>(h)</akn:num><akn:heading>Collection of unpaid fees</akn:heading><akn:content><akn:p>(h) Collection of unpaid fees In any case where the Secretary does not receive payment of a fee assessed under subsection (a) within 30 days after it is due, such fee shall be treated as a claim of the United States Government subject to subchapter II of chapter 37 of title 31.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_21_i"><akn:num>(i)</akn:num><akn:heading>Written requests for waivers, reductions, and refunds</akn:heading><akn:content><akn:p>(i) Written requests for waivers, reductions, and refunds To qualify for consideration for a waiver or reduction under subsection (d), or for a refund of any fee collected in accordance with subsection (a), a person shall submit to the Secretary a written request for such waiver, reduction, or refund not later than 180 days after such fee is due.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_21_j"><akn:num>(j)</akn:num><akn:heading>Construction</akn:heading><akn:content><akn:p>(j) Construction This section may not be construed to require that the number of full-time equivalent positions in the Department of Health and Human Services, for officers, employees, and advisory committees not engaged in the process of the review of abbreviated applications for generic new animal drugs, be reduced to offset the number of officers, employees, and advisory committees so engaged.</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>